Bernard H Bochner

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc The psychological context of quality of life: a psychometric analysis of a novel idiographic measure of bladder cancer patients' personal goals and concerns prior to surgery
    Bradley Andrew Morganstern
    Albert Einstein College of Medicine of Yeshiva University, 1300 Morris Park Avenue, Bronx, New York 10461, USA
    Health Qual Life Outcomes 9:10. 2011
  2. ncbi request reprint Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer
    Bernard H Bochner
    Department of Urology, Memorial Sloan Kettering Cancer Center, Kimmel Center for Prostate and Urologic Tumors, 353 E 68th St, New York, NY 10021, USA
    J Clin Oncol 24:3967-72. 2006
  3. doi request reprint Optimal timing of radical cystectomy for patients with T1 bladder cancer
    Bernard H Bochner
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Urol Oncol 27:329-31. 2009
  4. ncbi request reprint Intravesical bacillus Calmette-Guérin combined with electromotive mitomycin for high-risk superficial bladder cancer
    Bernard H Bochner
    Department of Urology, Memorial Sloan Kettering Cancer Center, Kimmel Center for Prostate and Urologic Cancers, 353 E 68th Street, New York, NY 10021, USA
    Nat Clin Pract Oncol 3:474-5. 2006
  5. doi request reprint Ureteroileocecal appendicostomy based urinary reservoir in irradiated and nonirradiated patients
    Bernard H Bochner
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Kimmel Center for Prostate and Urologic Cancers, New York, New York 10021, USA
    J Urol 182:2376-80. 2009
  6. ncbi request reprint Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping
    Bernard H Bochner
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 172:1286-90. 2004
  7. ncbi request reprint Use of an ureteroileocecal appendicostomy urinary reservoir in patients with recurrent pelvic malignancies treated with radiation
    Bernard H Bochner
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 94:140-6. 2004
  8. doi request reprint Gene therapy in bladder cancer
    Bernard H Bochner
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer, New York, New York 10021, USA
    Curr Opin Urol 18:519-23. 2008
  9. ncbi request reprint Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer
    Bernard H Bochner
    Department of Urology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, 1275 York Avenue, Kimmel Bldg, New York, NY 10021, USA
    Urol Clin North Am 30:777-89. 2003
  10. pmc A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience
    Atreya Dash
    Division of Urology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 113:2471-7. 2008

Detail Information

Publications70

  1. pmc The psychological context of quality of life: a psychometric analysis of a novel idiographic measure of bladder cancer patients' personal goals and concerns prior to surgery
    Bradley Andrew Morganstern
    Albert Einstein College of Medicine of Yeshiva University, 1300 Morris Park Avenue, Bronx, New York 10461, USA
    Health Qual Life Outcomes 9:10. 2011
    ..Our evaluation of this measure is a prelude to a prospective comparison of quality of life outcomes of reconstructive procedures after cystectomy...
  2. ncbi request reprint Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer
    Bernard H Bochner
    Department of Urology, Memorial Sloan Kettering Cancer Center, Kimmel Center for Prostate and Urologic Tumors, 353 E 68th St, New York, NY 10021, USA
    J Clin Oncol 24:3967-72. 2006
    ..The goal of this study was the development of a prognostic outcomes nomogram to predict the 5-year disease recurrence risk after radical cystectomy...
  3. doi request reprint Optimal timing of radical cystectomy for patients with T1 bladder cancer
    Bernard H Bochner
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Urol Oncol 27:329-31. 2009
    ..This article reviews the various features associated with an increased risk of disease progression to provide a framework for optimizing the timing of radical cystectomy...
  4. ncbi request reprint Intravesical bacillus Calmette-Guérin combined with electromotive mitomycin for high-risk superficial bladder cancer
    Bernard H Bochner
    Department of Urology, Memorial Sloan Kettering Cancer Center, Kimmel Center for Prostate and Urologic Cancers, 353 E 68th Street, New York, NY 10021, USA
    Nat Clin Pract Oncol 3:474-5. 2006
  5. doi request reprint Ureteroileocecal appendicostomy based urinary reservoir in irradiated and nonirradiated patients
    Bernard H Bochner
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, Kimmel Center for Prostate and Urologic Cancers, New York, New York 10021, USA
    J Urol 182:2376-80. 2009
    ..We report our experience with this reservoir to compare complications in irradiated and nonirradiated patients...
  6. ncbi request reprint Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping
    Bernard H Bochner
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 172:1286-90. 2004
    ..We prospectively evaluated RC cases with transitional cell carcinoma of the bladder to determine which factors may contribute to the variability in the number of reported LNs...
  7. ncbi request reprint Use of an ureteroileocecal appendicostomy urinary reservoir in patients with recurrent pelvic malignancies treated with radiation
    Bernard H Bochner
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Gynecol Oncol 94:140-6. 2004
    ..Evaluation of a modified right colon urinary reservoir in a heavily radiated patient population undergoing pelvic exenteration...
  8. doi request reprint Gene therapy in bladder cancer
    Bernard H Bochner
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer, New York, New York 10021, USA
    Curr Opin Urol 18:519-23. 2008
    ..Several gene therapy strategies have been studied in the treatment of bladder tumors. In this review, an update of the recent outcomes of viral-based gene therapy for bladder cancer is discussed...
  9. ncbi request reprint Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer
    Bernard H Bochner
    Department of Urology, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, 1275 York Avenue, Kimmel Bldg, New York, NY 10021, USA
    Urol Clin North Am 30:777-89. 2003
    ..Because of the ever-increasing fiscal constraints placed on clinicians, risk-adjusted follow-up strategies are reasonable, but will require prospective evaluation to validate their appropriateness...
  10. pmc A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience
    Atreya Dash
    Division of Urology, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 113:2471-7. 2008
    ..Gemcitabine plus cisplatin (GC) has similar efficacy and less toxicity than MVAC in metastatic disease, but is untested as neoadjuvant treatment...
  11. doi request reprint Clinical outcomes of primary bladder carcinoma in situ in a contemporary series
    Daher C Chade
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 184:74-80. 2010
    ..We describe patterns of disease recurrence and progression, and identify clinical outcome predictors of primary carcinoma in situ after bacillus Calmette-Guerin therapy...
  12. ncbi request reprint Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract
    Matthew D Galsky
    Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 69:255-9. 2007
    ..A unifying feature of these malignancies is their aggressive course and poor outcome with standard chemotherapeutic regimens. Given the rarity of these tumors, no prospective data are available to guide management...
  13. doi request reprint Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique?
    Ricardo L Favaretto
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10065, USA
    Eur Urol 58:645-51. 2010
    ..Questions remain regarding the oncologic safety of LRN and its relative equivalence to ORN...
  14. doi request reprint Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma
    Ricardo L Favaretto
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 109:77-82. 2012
    ....
  15. doi request reprint Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma
    Behfar Ehdaie
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BJU Int 111:589-95. 2013
    ..In addition, competing risks analyses showed that although current smoking did not increase the risk of recurrence, it imparted a significant risk of dying compared with former and never smoking...
  16. ncbi request reprint Significance of intraoperative ureteral evaluation at radical cystectomy for urothelial cancer
    Ganesh V Raj
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 107:2167-72. 2006
    ..In an attempt to reduce this recurrence risk, urologists employ intraoperative frozen sections to achieve an uninvolved ureteral margin. The utility of this surgical approach was examined...
  17. doi request reprint Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer
    David S Yee
    Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 183:1751-6. 2010
    ..We compared the outcomes of patients with bladder cancer previously treated for prostate cancer with radiotherapy vs other treatment modalities...
  18. doi request reprint Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer
    Theresa M Koppie
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer 112:2384-92. 2008
    ..Also evaluated was whether ACCI was associated with clinicopathologic and treatment characteristics...
  19. ncbi request reprint Natural history of positive urinary cytology after radical cystectomy
    Ganesh V Raj
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 176:2000-5; discussion 2005. 2006
    ..The natural history and risk of disease progression in patients with positive urine cytology after radical cystectomy for urothelial carcinoma has not been adequately elucidated...
  20. ncbi request reprint Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection
    Jeffrey M Holzbeierlein
    Department of Urology, Memorial Sloan Kettering Cancer Center, 353 E 68th Street, New York, NY 10021, USA
    J Urol 172:878-81. 2004
    ..This study analyzes the outcomes of partial cystectomy in a contemporary cohort of patients to identify appropriate selection criteria for the procedure...
  21. ncbi request reprint Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer
    Ganesh V Raj
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 177:1283-6; discussion 1286. 2007
    ..In this study we explored the effect of this paradigm shift on progression rates and disease specific survival...
  22. doi request reprint Clinical outcome of primary versus secondary bladder carcinoma in situ
    Daher C Chade
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 184:464-9. 2010
    ..Differences in clinical outcome are still unclear between primary and secondary bladder carcinoma in situ. We compared the clinical outcomes of primary and secondary carcinoma in situ, and identified predictive factors...
  23. ncbi request reprint Longitudinal risk of upper tract recurrence following radical cystectomy for urothelial cancer and the potential implications for long-term surveillance
    William Tran
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 179:96-100. 2008
    ..However, these recurrence rates are based on statistical methodology that does not take censoring into account. We used landmark time analysis to determine whether the risk of upper tract recurrence changes over time...
  24. doi request reprint Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer
    Joshua J Meeks
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BJU Int 111:E325-30. 2013
    ..To describe the pathological outcomes of patients with muscle-invasive micropapillary bladder cancer who have undergone neoadjuvant chemotherapy...
  25. ncbi request reprint Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy
    Joseph A Pettus
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur Urol 53:370-5. 2008
    ....
  26. ncbi request reprint Evaluation of regional lymph node dissection in patients with upper urinary tract urothelial cancer
    Fernando P Secin
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Int J Urol 14:26-32. 2007
    ..We evaluated the manner in which the LND was applied at NU, the patterns of lymph node (LN) involvement and the preoperative variables that could identify patients at high risk for lymph node metastasis (LNM)...
  27. doi request reprint Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure
    Itay A Sternberg
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
    J Urol 190:1686-91. 2013
    ..We report our experience with intravesical gemcitabine for bladder cancer after failed bacillus Calmette-Guérin treatment...
  28. ncbi request reprint Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma
    Michael Mullerad
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 172:2177-81. 2004
    ..Overall 5-year disease specific survival is in the range of 16.5% to 95% depending on stage. In this study we evaluated predictors associated with disease recurrence and disease specific survival...
  29. pmc Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach
    Andrew J Vickers
    Department of Epidemiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 115:5460-9. 2009
    ....
  30. ncbi request reprint Standardization of pelvic lymphadenectomy performed at radical cystectomy: can we establish a minimum number of lymph nodes that should be removed?
    Theresa M Koppie
    Department of Urology, Sidney Kimmel Center for Urologic Cancer, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 107:2368-74. 2006
    ..The goal of the current study was to determine if a threshold number of nodes exists, above which taking additional LNs has no clinical benefit...
  31. ncbi request reprint Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors
    Eiji Kikuchi
    Departments of Urology and Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:4511-8. 2007
    ..In an attempt to improve viral delivery of potentially therapeutic genes via an intravesical route, we have recently developed murine leukemia virus-based replication-competent retrovirus (RCR) vectors...
  32. doi request reprint Lymph node-positive bladder cancer treated with radical cystectomy and lymphadenectomy: effect of the level of node positivity
    Tatum V Tarin
    Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    Eur Urol 61:1025-30. 2012
    ..The extent of lymphadenectomy needed to optimize oncologic outcomes after radical cystectomy (RC) for patients with regionally advanced bladder cancer (BCa) is unclear...
  33. ncbi request reprint Importance of node dissection in relation to neoadjuvant and adjuvant therapy
    William C Huang
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, 10021, USA
    J Natl Compr Canc Netw 4:1019-26. 2006
    ....
  34. ncbi request reprint Urachal carcinoma: contemporary surgical outcomes
    Harry W Herr
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 178:74-8; discussion 78. 2007
    ..We determined surgical outcomes in a contemporary series of patients who underwent surgery for urachal carcinoma...
  35. doi request reprint Regional lymph node status in patients with bladder cancer found to be pathological stage T0 at radical cystectomy following systemic chemotherapy
    Matthew G Kaag
    Department of Surgery, Urology Section, Memorial Sloan Kettering Cancer Center, 1275 York Ave Box 213, New York, NY 10065, USA
    BJU Int 108:E272-7. 2011
    ..To evaluate the effect of preoperative cisplatin-based chemotherapy on the regional lymph nodes of patients with bladder cancer who attain pathological T0 status in the bladder after chemotherapy followed by radical cystectomy...
  36. doi request reprint Lymphadenectomy for bladder cancer at the time of radical cystectomy
    Derya Tilki
    Department of Urology, University of California, Davis, Medical Center, Sacramento, CA 95817, USA
    Eur Urol 64:266-76. 2013
    ....
  37. doi request reprint Upper tract imaging surveillance is not effective in diagnosing upper tract recurrence in patients followed for nonmuscle invasive bladder cancer
    Itay A Sternberg
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
    J Urol 190:1187-91. 2013
    ..We evaluated the usefulness of routine upper tract imaging in patients followed for nonmuscle invasive bladder cancer...
  38. doi request reprint Urinary diversion practice patterns among certifying American urologists
    Jonathan L Silberstein
    Department of Surgery, Sidney Kimmel Center for Prostate and Urologic Cancers, New York, New York 10065, USA
    J Urol 189:1042-7. 2013
    ..We investigated trends in urinary diversion use and surgeon characteristics in the performance of incontinent and continent urinary diversion using American Board of Urology data...
  39. ncbi request reprint Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients
    Ofer Yossepowitch
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 176:482-5. 2006
    ..We assessed the safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients...
  40. ncbi request reprint Radical cystectomy and lymphadenectomy for invasive bladder cancer: towards the evolution of an optimal surgical standard
    Ganesh V Raj
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 34:110-21. 2007
    ..This ongoing evolution in the technique of RC and pelvic lymph node dissection (PLND) may help define a new surgical standard that provides optimal benefit in patients with invasive bladder cancer...
  41. doi request reprint The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center
    Ricardo L Favaretto
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur Urol 58:574-80. 2010
    ..The prognostic impact of primary tumor location on outcomes for patients with upper-tract urothelial carcinoma (UTUC) is still contentious...
  42. ncbi request reprint Orthotopic urinary diversion after cystectomy for bladder cancer: implications for cancer control and patterns of disease recurrence
    Ofer Yossepowitch
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Urol 169:177-81. 2003
    ..The impact of orthotopic urinary diversion on the quality of cystectomy and ensuing cancer control has not been adequately studied. We analyzed our experience with this clinical problem...
  43. doi request reprint Does minimally invasive surgery for radical cystectomy provide similar long-term cancer control as open radical surgery?
    Gal E Keren Paz
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Curr Opin Urol 23:449-55. 2013
    ..This review focuses on the present state of the literature regarding the oncological efficacy of minimally invasive radical cystectomy (MIRC) and PLND...
  44. doi request reprint A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer
    Joshua J Meeks
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur Urol 62:523-33. 2012
    ..Muscle-invasive bladder cancer (MIBC) is a disease with a pattern of predominantly distant and early recurrences. Neoadjuvant cisplatin-based combination chemotherapy has demonstrated improved outcomes for MIBC...
  45. doi request reprint Pelvic exenteration with curative intent for recurrent uterine malignancies
    Fady Khoury-Collado
    Department of Surgery, Gynecology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Gynecol Oncol 124:42-7. 2012
    ..To evaluate the outcomes observed with pelvic exenteration with curative intent for recurrent uterine malignancies in the modern era...
  46. doi request reprint Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology
    Ahmad Shabsigh
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States
    Eur Urol 55:164-74. 2009
    ..Reporting methodology is highly variable and nonstandardized, yet surgical outcomes are utilized in clinical trial design and evaluation of healthcare provider performance...
  47. doi request reprint Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience
    S Machele Donat
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, United States
    Eur Urol 55:177-85. 2009
    ..However, in a recent report from the National Cancer Database (NCDB), only 11.6% of stage III BCa patients received perioperative chemotherapy, the majority in the adjuvant setting...
  48. ncbi request reprint Superficial and muscle-invasive bladder cancer: principles of management for outcomes assessments
    Dipen J Parekh
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:5519-27. 2006
    ..Well-designed trials with effective chemotherapy have shown a beneficial role for neoadjuvant chemotherapy...
  49. pmc Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma
    Michael Mullerad
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 174:741-6. 2005
    ....
  50. ncbi request reprint Use of nomograms as predictive tools in bladder cancer
    Ahmad Shabsigh
    Division of Urology, Memorial Sloan Kettering Cancer Center, Kimmel Center for Prostate and Urologic Cancers, 353 E 68th Street, New York, NY 10021, USA
    World J Urol 24:489-98. 2006
    ..We summarize the current status of outcome predictive models for bladder cancer; and focus particularly on the ability of nomograms to predict disease recurrence, progression, and patient survival...
  51. ncbi request reprint Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer
    Harry W Herr
    Departments of Urology Genitourinary Oncology Service, Medicine and Pathology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 167:1295-8. 2002
    ..We postulate that the number of lymph nodes examined in cystectomy specimens can have an impact on the outcome of patients with bladder cancer...
  52. ncbi request reprint Prognostic significance of p27Kip1 expression in bladder cancer
    Farhang Rabbani
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    BJU Int 100:259-63. 2007
    ....
  53. doi request reprint The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer
    Philip H Kim
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    World J Urol 32:453-9. 2014
    ..We investigated smoking as a potential predictor for pathologic outcomes after neoadjuvant chemotherapy (NC) and radical cystectomy (RC) for muscle-invasive bladder cancer...
  54. doi request reprint Pubovesical fistula: a rare complication after treatment of prostate cancer
    Kazuhito Matsushita
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Urology 80:446-51. 2012
    ....
  55. doi request reprint Initial results with (11)C-acetate positron emission tomography/computed tomography (PET/CT) in the staging of urinary bladder cancer
    Heiko Schoder
    Department of Radiology, Nuclear Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mol Imaging Biol 14:245-51. 2012
    ..To investigate the utility of (11)C-acetate positron emission tomography/computed tomography (PET/CT) for staging of bladder cancer and response assessment after neoadjuvant chemotherapy...
  56. doi request reprint A plea for a uniform surveillance schedule after radical cystectomy
    Guido Dalbagni
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 185:2091-6. 2011
    ..We identified the pattern of post-cystectomy surveillance recommended in the oncologic community and assessed compliance to a predetermined schedule among a small group of urologists...
  57. doi request reprint The effect of age and gender on bladder cancer: a critical review of the literature
    Shahrokh F Shariat
    Division of Urology Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BJU Int 105:300-8. 2010
    ..We must strive to develop transdisciplinary collaborative efforts to provide tailored gender- and age-specific care for patients with UCB...
  58. ncbi request reprint Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder
    Atreya Dash
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 107:506-13. 2006
    ..Renal impairment may be a major factor limiting its use. The current study was designed to determine the proportion of patients ineligible to receive adjuvant cisplatin-based chemotherapy based on inadequate renal function alone...
  59. ncbi request reprint Current status of establishing standards for lymphadenectomy in the treatment of bladder cancer
    William C Huang
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Curr Opin Urol 15:315-9. 2005
    ..We reviewed the past and contemporary literature to clarify the current role of pelvic lymph node dissection both as a staging modality as well as potential therapeutic intervention...
  60. ncbi request reprint Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer
    Susannah M Mourton
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, MRI 1026, New York, NY 10021, USA
    Gynecol Oncol 99:608-14. 2005
    ..The aim of this study was to assess the morbidity associated with en bloc resection of ovarian carcinoma with low anterior resection and anastomosis in patients undergoing primary cytoreductive surgery for advanced disease...
  61. ncbi request reprint Association between urinary cytology and pathology for nontransitional cell malignancies of the urinary tract
    Ganesh V Raj
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 175:2038-41; discussion 2041. 2006
    ..Because nontransitional cell carcinoma neoplasms of the urinary tract are rare in Western countries, we examined the association between urinary cytology and pathology evaluations for these tumors...
  62. doi request reprint Summary of the 6th Annual Bladder Cancer Think Tank: new directions in urologic research
    Robert S Svatek
    Department of Urology, UT Health Science Center San Antonio, San Antonio, TX 78229, USA
    Urol Oncol 31:968-73. 2013
    ....
  63. pmc Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer
    Gopa Iyer
    Memorial Sloan Kettering Cancer Center, Cornell University, New York, NY, USA
    J Clin Oncol 31:3133-40. 2013
    ..We sought to define the prevalence and co-occurrence of actionable genomic alterations in patients with high-grade bladder cancer to serve as a platform for therapeutic drug discovery...
  64. doi request reprint Bladder cancer imaging: an update
    Kelvin A Moses
    Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Curr Opin Urol 21:393-7. 2011
    ..To present the recent advances in imaging for diagnosis, staging, and follow-up of bladder cancer...
  65. doi request reprint Oncological outcomes after radical cystectomy for bladder cancer: open versus minimally invasive approaches
    Daher C Chade
    Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Urol 183:862-69. 2010
    ..In this review we summarize the most comprehensive articles published on the oncological outcomes of laparoscopic assisted, robotic assisted and open radical cystectomy...
  66. ncbi request reprint A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer
    Marta Sanchez-Carbayo
    Division of Molecular Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 13:3215-20. 2007
    ..In this study, we aim to evaluate the SNP309 in bladder cancer and to link it to TP53 status...
  67. ncbi request reprint Importance of lymph node dissection in urologic cancers
    Bernard H Bochner
    Department of Urology, Memorial Sloan Kettering Cancer Center, Kimmel Center for Prostate and Urologic Cancers, New York, NY, 10021 USA
    Urol Oncol 22:197. 2004
  68. ncbi request reprint Inhibition of orthotopic human bladder tumor growth by lentiviral gene transfer of endostatin
    Eiji Kikuchi
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 10:1835-42. 2004
    ..The purpose of this study was to investigate whether local overexpression of endostatin could serve to diminish tumor growth of bladder cancer in vivo...
  69. ncbi request reprint Detection of methylated apoptosis-associated genes in urine sediments of bladder cancer patients
    Martin G Friedrich
    Departments of Urology, Clinical Pathology, and Preventive Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California 90089 9176, USA
    Clin Cancer Res 10:7457-65. 2004
    ....
  70. ncbi request reprint Multimodal therapy for urologic cancers
    Bernard H Bochner
    Nat Clin Pract Urol 3:453. 2006